Desk›Healthcare› Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd
BSE 524742 · NSE CAPLIPOINT · ISIN INE475E01026 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹2,542.15
+0.92%
BSE close, 28 August 2026
₹19,323.31 cr
7.6 cr shares · Small cap
₹5,085.64 cr
as published
46.0× · 12.59×
EPS ₹55.22 · BV ₹201.92
738.33 / 396.58
₹ cr, as filed
23
6 selected · 26%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -5.8% |
|---|---|
| Against 52-week low | +69.2% |
| Day change | +0.92% |
| Size band | Small cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹55.22 |
|---|---|
| Price / earnings | 46.04× |
| Price / book | 12.59× |
| Book value — derived, price ÷ P/B | ₹201.92 |
| Return on equity | 27.35% |
| Operating margin | 77.46% |
| Net margin | 59.32% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 27.35%
- ROE as published
- 27.35%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 202.95 | 120.38 | 15.84 | 77.46% | 59.32% |
| Mar-26 · Q | 191.36 | 109.50 | 15.89 | 75.60% | 57.22% |
| FY25-26 | 738.33 | 396.58 | 52.17 | 72.21% | 53.71% |
Quarter on quarter
- Revenue, quarter on quarter
- +6.1%
- Net profit, quarter on quarter
- +9.9%
- Operating margin, quarter on quarter
- +186 bps
Disclosure profile 23 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Dividend | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 6 |
| Procedural | |
| General | 4 |
| AGM / EGM | 3 |
| Analyst / Investor Meet | 2 |
| Newspaper Publication | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Clarification | 1 |
| Compliance Certificate | 1 |
| Trading Window | 1 |
| Procedural sub-total | 17 |
| Total | 23 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
23 filings · 6 selected · busiest 2026-08-12
Filing rhythm · the twelve most recent
2026-09-022026-10-07
SelectedProcedural
Filings
23 in the window · 1 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Results and Scrutinizer Report for the 35th Annual General Meeting
AGM/EGM / AGM View filing →
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 35th Annual General Meeting of the Company
AGM/EGM / AGM View filing →
-
25 September 2026 ·
Clarification With Respect To Volume Movement
Clarification with respect to Volume Movement
Company Update / General View filing →
-
25 September 2026 ·
Clarification sought from Caplin Point Laboratories Ltd
The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 25, 2026, with reference to Movement in Volume. The reply is awaited.
Company Update / Clarification
-
4 September 2026 ·
Newspaper Publication
Newspaper Publication for Notice of 35th AGM and E-Voting Information
Company Update / Newspaper Publication View filing →
-
4 September 2026 ·
Letter To Shareholders
Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-26
Company Update / General View filing →
-
3 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
3 September 2026 ·
Notice Of The 35Th Annual General Meeting
Notice of the 35th Annual General Meeting of the Company
AGM/EGM / AGM View filing →
-
3 September 2026 ·
Reg. 34 (1) Annual Report.
Annual Report for the Financial Year 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
2 September 2026 ·
Newspaper Publication
Newspaper Publication for convening 35th AGM of the Company through Video Conferencing.
Company Update / Newspaper Publication View filing →
-
1 September 2026 ·
General Updates
Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA
Company Update / General View filing →
-
21 August 2026 ·
General Updates
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company's subsidiary)
Company Update / General View filing →
-
19 August 2026 ·
Earnings Call Transcript
Transcript for Earnings call- Q1- FY 2026-27
Company Update / Earnings Call Transcript View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of Earnings call for the Quarter ended June 30, 2026
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Investor Presentation
Investor Presentation for the Earnings Call for the Quarter ended June 30, 2026.
Company Update / Investor Presentation View filing →
-
12 August 2026 ·
Change in Management
The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.
Company Update / Change in Management View filing →
-
12 August 2026 ·
Results For Quarter Ended June 30, 2026
Financial Results for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
12 August 2026 ·
Corporate Action-Board approves Dividend
Record date for Final Dividend is September 18, 2026
Corp. Action / Dividend View filing →
-
12 August 2026 ·
Board Meeting Outcome for Meeting Held On August 12, 2026
Board meeting outcome for meeting held on August 12, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
30 July 2026 ·
Analyst / Investor Meet - Intimation
Post-results conference call invite for the quarter ended June 30, 2026 is enclosed herewith.
Company Update / Analyst / Investor Meet View filing →
-
29 July 2026 ·
Board Meeting Intimation for Approval Of Financial Results And Recommendation Of Final Dividend, If Any.
Caplin Point Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Caplin Point Laboratories Ltd · the 50 most recent filings